Liquid formulation development

Liquid formulation development

Screening

Information

By following our mission of “Formulating innovation”, we combine technologies, knowledge and experience to add substantial financial value to our customer’s projects by: generating IP for your pharmaceutical compound to support formulation patent application, supporting patent life cycle management in later phases, reducing time-to-market with tailor-made development strategies, increasing value of your drug development project for out-licensing and M&A activities. Coriolis will seek no financial participation in generated IP – no royalties, no milestone payments. Click the link below to find out more!
Link
https://www.coriolis-pharma.com/formulation-development/liquid-formulations
Coriolis PharmaMore than 600 customers trust the expertise of Coriolis. We develop liquid and lyophilized formulations out of one hand: no subcontracting to third parties. For each individual project, our highly skilled scientists develop tailor-made study designs that align with our customers’ drug development strategy. We do not force your molecule through an existing platform but create knowledge-driven innovative solutions. Our formulation services support all phases of drug development and our customers rely on Coriolis for trouble-shooting, batch-release analysis and formulation optimization even beyond market approval. We are specialized in: ·        Pre-formulation and candidate selection ·        Early stage formulation development ·        Late phase formulation development ·        Lyophilization cycle optimization ·        Scale – up and transfer studies ·        Developability / manufacturability assessment ·        Support in container closure system selection ·        In-use stability studies ·        Stability testing including forced degradation studies ·        R&D and cGMP-compliant contract analytical services ·        Orthogonal analysis of subvisible aggregates and particles Coriolis can draw from a unique analytical portfolio of more than 100 different techniques – entirely performed in-house – to obtain orthogonal and meaningful data. We offer all our services under Biosafety level 1 by default and a large selection also under Biosafety level 2. Dedicated GMP facilities with full involvement of Quality Management enable us to conduct lot-release analysis and generate supportive data for market approval and allow for tailored “enhanced R&D” level studies (e.g., qualified equipment but no QA involvement). Coriolis provides state-of-the-art as well as promising new and emerging technologies in the field of: ·        Particle characterization (from nanometer to visible) ·        Aggregate analytics ·        Surfactant characterization ·        Higher order structure analysis ·        Chemical changes  

Log in

See all the content and easy-to-use features by logging in or registering!